Risk factors for severe COVID-19 among patients with systemic lupus erythematosus: a real-world analysis of a large representative US administrative claims database, 2020–2021
Objectives To identify risk factors for progression to severe COVID-19 and estimate the odds of severe COVID-19 associated with vaccination among patients with systemic lupus erythematosus (SLE).Methods This retrospective cohort study identified adults with SLE in the Merative™ MarketScan® Databases...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-07-01
|
| Series: | RMD Open |
| Online Access: | https://rmdopen.bmj.com/content/9/3/e003250.full |
| _version_ | 1827773874331189248 |
|---|---|
| author | Cassandra Calabrese Gelareh Atefi Kristin A Evans Meghan Moynihan Liisa Palmer Sze-Jung Wu |
| author_facet | Cassandra Calabrese Gelareh Atefi Kristin A Evans Meghan Moynihan Liisa Palmer Sze-Jung Wu |
| author_sort | Cassandra Calabrese |
| collection | DOAJ |
| description | Objectives To identify risk factors for progression to severe COVID-19 and estimate the odds of severe COVID-19 associated with vaccination among patients with systemic lupus erythematosus (SLE).Methods This retrospective cohort study identified adults with SLE in the Merative™ MarketScan® Databases. Patients were continuously enrolled the year before 1 April 2020 (baseline) and had a COVID-19 diagnosis between 1 April 2020 and the earliest of death, enrolment end or 31 December 2021. Severe COVID-19 was defined as hospitalisation with a COVID-19 diagnosis. Demographics on 1 April 2020, baseline comorbidities, corticosteroid use ≤30 days before COVID-19 diagnosis and other SLE medication use ≤6 months before COVID-19 diagnosis were assessed. Vaccination was identified by claims for a COVID-19 vaccine or vaccine administration. Backward stepwise logistic regression estimated odds of progression to severe COVID-19 associated with patient characteristics and vaccination.Results Among 2890 patients with SLE with COVID-19, 500 (16.4%) had a COVID-19-related hospitalisation. Significant risk factors for progression to severe COVID-19 included rituximab (OR (95% CI) 2.92 (1.67 to 5.12)), renal failure (2.15 (95% CI 1.56 to 2.97)), Medicaid (vs Commercial; 2.01 (95% CI 1.58 to 2.57)), complicated hypertension (1.96 (95% CI 1.38 to 2.77)) and time of infection, among others. Vaccination had a significant protective effect (0.68(95% CI 0.54 to 0.87)) among all patients with SLE with COVID-19, but the effect was not significant among those with prior use of belimumab, rituximab or corticosteroids.Conclusions Certain chronic comorbidities and SLE medications increase the odds of progression to severe COVID-19 among patients with SLE, but vaccination confers significant protection. Vaccine effectiveness may be attenuated by SLE treatments. Protective measures such as pre-exposure prophylaxis and booster vaccines should be encouraged among patients with SLE. |
| first_indexed | 2024-03-11T13:29:01Z |
| format | Article |
| id | doaj.art-ed5f371b7e624ba69ffbecaad2dcbce7 |
| institution | Directory Open Access Journal |
| issn | 2056-5933 |
| language | English |
| last_indexed | 2024-03-11T13:29:01Z |
| publishDate | 2023-07-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | RMD Open |
| spelling | doaj.art-ed5f371b7e624ba69ffbecaad2dcbce72023-11-03T04:30:06ZengBMJ Publishing GroupRMD Open2056-59332023-07-019310.1136/rmdopen-2023-003250Risk factors for severe COVID-19 among patients with systemic lupus erythematosus: a real-world analysis of a large representative US administrative claims database, 2020–2021Cassandra Calabrese0Gelareh Atefi1Kristin A Evans2Meghan Moynihan3Liisa Palmer4Sze-Jung Wu5Rheumatic & Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio, USAUS Medical, AstraZeneca Pharmaceuticals LP, Wilmington, Delaware, USAReal World Data Research and Analytics, Merative, Ann Arbor, Michigan, USAReal World Data Research and Analytics, Merative, Ann Arbor, Michigan, USAReal World Data Research and Analytics, Merative, Ann Arbor, Michigan, USAUS Medical, AstraZeneca Pharmaceuticals LP, Wilmington, Delaware, USAObjectives To identify risk factors for progression to severe COVID-19 and estimate the odds of severe COVID-19 associated with vaccination among patients with systemic lupus erythematosus (SLE).Methods This retrospective cohort study identified adults with SLE in the Merative™ MarketScan® Databases. Patients were continuously enrolled the year before 1 April 2020 (baseline) and had a COVID-19 diagnosis between 1 April 2020 and the earliest of death, enrolment end or 31 December 2021. Severe COVID-19 was defined as hospitalisation with a COVID-19 diagnosis. Demographics on 1 April 2020, baseline comorbidities, corticosteroid use ≤30 days before COVID-19 diagnosis and other SLE medication use ≤6 months before COVID-19 diagnosis were assessed. Vaccination was identified by claims for a COVID-19 vaccine or vaccine administration. Backward stepwise logistic regression estimated odds of progression to severe COVID-19 associated with patient characteristics and vaccination.Results Among 2890 patients with SLE with COVID-19, 500 (16.4%) had a COVID-19-related hospitalisation. Significant risk factors for progression to severe COVID-19 included rituximab (OR (95% CI) 2.92 (1.67 to 5.12)), renal failure (2.15 (95% CI 1.56 to 2.97)), Medicaid (vs Commercial; 2.01 (95% CI 1.58 to 2.57)), complicated hypertension (1.96 (95% CI 1.38 to 2.77)) and time of infection, among others. Vaccination had a significant protective effect (0.68(95% CI 0.54 to 0.87)) among all patients with SLE with COVID-19, but the effect was not significant among those with prior use of belimumab, rituximab or corticosteroids.Conclusions Certain chronic comorbidities and SLE medications increase the odds of progression to severe COVID-19 among patients with SLE, but vaccination confers significant protection. Vaccine effectiveness may be attenuated by SLE treatments. Protective measures such as pre-exposure prophylaxis and booster vaccines should be encouraged among patients with SLE.https://rmdopen.bmj.com/content/9/3/e003250.full |
| spellingShingle | Cassandra Calabrese Gelareh Atefi Kristin A Evans Meghan Moynihan Liisa Palmer Sze-Jung Wu Risk factors for severe COVID-19 among patients with systemic lupus erythematosus: a real-world analysis of a large representative US administrative claims database, 2020–2021 RMD Open |
| title | Risk factors for severe COVID-19 among patients with systemic lupus erythematosus: a real-world analysis of a large representative US administrative claims database, 2020–2021 |
| title_full | Risk factors for severe COVID-19 among patients with systemic lupus erythematosus: a real-world analysis of a large representative US administrative claims database, 2020–2021 |
| title_fullStr | Risk factors for severe COVID-19 among patients with systemic lupus erythematosus: a real-world analysis of a large representative US administrative claims database, 2020–2021 |
| title_full_unstemmed | Risk factors for severe COVID-19 among patients with systemic lupus erythematosus: a real-world analysis of a large representative US administrative claims database, 2020–2021 |
| title_short | Risk factors for severe COVID-19 among patients with systemic lupus erythematosus: a real-world analysis of a large representative US administrative claims database, 2020–2021 |
| title_sort | risk factors for severe covid 19 among patients with systemic lupus erythematosus a real world analysis of a large representative us administrative claims database 2020 2021 |
| url | https://rmdopen.bmj.com/content/9/3/e003250.full |
| work_keys_str_mv | AT cassandracalabrese riskfactorsforseverecovid19amongpatientswithsystemiclupuserythematosusarealworldanalysisofalargerepresentativeusadministrativeclaimsdatabase20202021 AT gelarehatefi riskfactorsforseverecovid19amongpatientswithsystemiclupuserythematosusarealworldanalysisofalargerepresentativeusadministrativeclaimsdatabase20202021 AT kristinaevans riskfactorsforseverecovid19amongpatientswithsystemiclupuserythematosusarealworldanalysisofalargerepresentativeusadministrativeclaimsdatabase20202021 AT meghanmoynihan riskfactorsforseverecovid19amongpatientswithsystemiclupuserythematosusarealworldanalysisofalargerepresentativeusadministrativeclaimsdatabase20202021 AT liisapalmer riskfactorsforseverecovid19amongpatientswithsystemiclupuserythematosusarealworldanalysisofalargerepresentativeusadministrativeclaimsdatabase20202021 AT szejungwu riskfactorsforseverecovid19amongpatientswithsystemiclupuserythematosusarealworldanalysisofalargerepresentativeusadministrativeclaimsdatabase20202021 |